pipette
ESEspañol

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

Sean Wharton, Carel Wynand le Roux, Elena Startseva, Isabel M. Kloer, Ahmad Alhussein, Samina Ajaz Hussain, Anna Unseld, Biykem Bozkurt, Jamy D. Ard, Harold Edward Bays, Paweł Bogdański, Jawad H. Butt, Elif Ilhan Ekinci, Ania M. Jastreboff, Linong Ji, Morten Schou, Francisco José Tinahones, Alexander D. Kokkinos, Béla Péter Merkely, Wataru Ogawa, Sue D. Pedersen, Kirsi Hannele Pietiläinen, Dean Quinn, Naveed A. Sattar, Jochen Seufert, Kaj Stenlöf, André P. van Beek, Roman Vangoitsenhoven, Martina Brueckmann, Ramy Younes, Lee M. Kaplan

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
ConclusionsIn adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo.

Appeared: Saturday, October 3. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2607219